CA2748931A1 - Methods and compositions containing mtor inhibitors for enhancing immune responses - Google Patents

Methods and compositions containing mtor inhibitors for enhancing immune responses Download PDF

Info

Publication number
CA2748931A1
CA2748931A1 CA2748931A CA2748931A CA2748931A1 CA 2748931 A1 CA2748931 A1 CA 2748931A1 CA 2748931 A CA2748931 A CA 2748931A CA 2748931 A CA2748931 A CA 2748931A CA 2748931 A1 CA2748931 A1 CA 2748931A1
Authority
CA
Canada
Prior art keywords
cells
antigen
mtor
rapamycin
individual
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2748931A
Other languages
English (en)
French (fr)
Inventor
Hyung Kim
Protul Shrikant
Yanping Wang
Qingsheng Li
Rajesh Rao
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Health Research Inc
Original Assignee
Health Research Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Health Research Inc filed Critical Health Research Inc
Publication of CA2748931A1 publication Critical patent/CA2748931A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/26—Lymph; Lymph nodes; Thymus; Spleen; Splenocytes; Thymocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/208—IL-12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A61K2039/55527—Interleukins
    • A61K2039/55538—IL-12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6043—Heat shock proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/57—Skin; melanoma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/59—Reproductive system, e.g. uterus, ovaries, cervix or testes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Developmental Biology & Embryology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CA2748931A 2009-01-14 2010-01-14 Methods and compositions containing mtor inhibitors for enhancing immune responses Abandoned CA2748931A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US14453709P 2009-01-14 2009-01-14
US61/144,537 2009-01-14
US29309610P 2010-01-07 2010-01-07
US61/293,096 2010-01-07
PCT/US2010/021029 WO2010083298A1 (en) 2009-01-14 2010-01-14 Methods and compositions containing mtor inhibitors for enhancing immune responses

Publications (1)

Publication Number Publication Date
CA2748931A1 true CA2748931A1 (en) 2010-07-22

Family

ID=42340082

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2748931A Abandoned CA2748931A1 (en) 2009-01-14 2010-01-14 Methods and compositions containing mtor inhibitors for enhancing immune responses

Country Status (6)

Country Link
US (1) US20100196311A1 (OSRAM)
EP (1) EP2375897A4 (OSRAM)
JP (1) JP2012515213A (OSRAM)
CN (1) CN102281761A (OSRAM)
CA (1) CA2748931A1 (OSRAM)
WO (1) WO2010083298A1 (OSRAM)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8906374B2 (en) 2010-04-20 2014-12-09 Cedars-Sinai Medical Center Combination therapy with CD4 lymphocyte depletion and mTOR inhibitors
CN104338129B (zh) * 2013-07-26 2017-05-24 中国科学院上海巴斯德研究所 雷帕霉素作为疫苗佐剂的用途及制备方法
CA2929181A1 (en) * 2013-11-13 2015-05-21 Novartis Ag Mtor inhibitors for enhancing the immune response
WO2015120198A1 (en) 2014-02-05 2015-08-13 Cedars-Sinai Medical Center Methods and compositions for treating cancer and infectious diseases
JP7054622B2 (ja) 2014-07-21 2022-04-14 ノバルティス アーゲー ヒト化抗ｂｃｍａキメラ抗原受容体を使用した癌の処置
WO2016014535A1 (en) 2014-07-21 2016-01-28 Novartis Ag Treatment of cancer using a cll-1 chimeric antigen receptor
EP3297629A1 (en) 2015-05-20 2018-03-28 Novartis AG Pharmaceutical combination of everolimus with dactolisib
EP3313409A4 (en) * 2015-06-29 2018-12-26 Abraxis BioScience, LLC Methods of treating hematological malignancy using nanoparticle mtor inhibitor combination therapy
LT3313401T (lt) 2015-06-29 2022-01-10 Abraxis Bioscience, Llc Nanodalelės, apimančios sirolimą ir albuminą, skirtos naudoti epitelioidinių ląstelių navikų gydymui
WO2017015024A1 (en) * 2015-07-20 2017-01-26 Mayo Foundation For Medical Education And Research Methods and materials for producing t cells
US11413309B2 (en) * 2016-01-20 2022-08-16 Fate Therapeutics, Inc. Compositions and methods for immune cell modulation in adoptive immunotherapies
EP3405567A4 (en) * 2016-01-20 2019-10-30 Fate Therapeutics, Inc. COMPOUNDS AND METHODS FOR IMMUNOCELL MODULATION IN ADOPTIVE IMMUNOTHERAPIES
AU2017363970A1 (en) 2016-11-23 2019-06-20 Novartis Ag Methods of enhancing immune response with everolimus, dactolisib or both
WO2018106595A1 (en) 2016-12-05 2018-06-14 Fate Therapeutics, Inc. Compositions and methods for immune cell modulation in adoptive immunotherapies
WO2019157516A1 (en) 2018-02-12 2019-08-15 resTORbio, Inc. Combination therapies
CN112203725A (zh) 2018-06-13 2021-01-08 诺华股份有限公司 Bcma嵌合抗原受体及其用途
CN110412289B (zh) * 2019-07-25 2022-08-02 北京美迪阿姆科技发展有限公司 抑制性t细胞及筛选方法和抑制自身免疫反应中的应用
CN114426952A (zh) * 2020-10-29 2022-05-03 中国科学技术大学 用于白血病的car t细胞疗法的t细胞增效剂及获得增效t细胞的方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999048524A1 (en) * 1998-03-03 1999-09-30 University Of Southern California Use of cytokines and mitogens to inhibit graft versus host disease
US7198789B2 (en) * 1998-03-17 2007-04-03 Genetics Institute, Llc Methods and compositions for modulating interleukin-21 receptor activity
WO2005003335A2 (en) * 2003-06-12 2005-01-13 Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Rapamycin resistant t cells and therapeutic uses thereof
US7718196B2 (en) * 2001-07-02 2010-05-18 The United States Of America, As Represented By The Department Of Health And Human Services Rapamycin-resistant T cells and therapeutic uses thereof
US20040258661A1 (en) * 2001-10-31 2004-12-23 Daniel Fowler Generation of use of tc1 and tc2 cells
US20060094674A1 (en) * 2002-07-05 2006-05-04 Neel Benjamin G Combination of mtor inhibitor and a tyrosine kinase inhibitor for the treatment of neoplasms
PT1408106E (pt) * 2002-10-11 2007-04-30 Sentoclone Ab Imunoterapia de cancro
CN102671196B (zh) * 2006-04-05 2014-12-03 诺华股份有限公司 用于治疗癌症的治疗剂的组合
US8119772B2 (en) * 2006-09-29 2012-02-21 California Institute Of Technology MART-1 T cell receptors
US8765462B2 (en) * 2007-05-04 2014-07-01 University Health Network IL-12 immunotherapy for cancer
US8840899B2 (en) * 2008-08-05 2014-09-23 Emory University Use of mTOR inhibitors to enhance T cell immune responses

Also Published As

Publication number Publication date
US20100196311A1 (en) 2010-08-05
EP2375897A1 (en) 2011-10-19
WO2010083298A1 (en) 2010-07-22
JP2012515213A (ja) 2012-07-05
EP2375897A4 (en) 2013-05-15
CN102281761A (zh) 2011-12-14

Similar Documents

Publication Publication Date Title
US20100196311A1 (en) METHODS AND COMPOSITIONS CONTAINING mTOR INHIBITORS FOR ENHANCING IMMUNE RESPONSES
Xu et al. Nanovaccine based on a protein-delivering dendrimer for effective antigen cross-presentation and cancer immunotherapy
Ashley et al. Bone marrow–generated dendritic cells pulsed with tumor extracts or tumor RNA induce antitumor immunity against central nervous system tumors
CN1805758B (zh) 核酸和细胞疫苗的组分
von Beust et al. Improving the therapeutic index of CpG oligodeoxynucleotides by intralymphatic administration
Schneeberger et al. CpG motifs are efficient adjuvants for DNA cancer vaccines
KR20100101094A (ko) 수지상 세포를 생산하는 방법
Lee et al. Induction of an antigen-specific, CD1-restricted cytotoxic T lymphocyte response in vivo
EP2351577A1 (en) Methods to trigger, maintain and manipulate immune responses by targeted administration of biological response modifiers into lymphoid organs
US20060073159A1 (en) Human anti-cancer immunotherapy
EP1165125A2 (en) Antigen-specific induction of peripheral immune tolerance
JP2008526763A (ja) 予防又は治療目的のｍｈｃクラスｉ拘束性エピトープに対する免疫応答の誘導、増強及び保持方法
Geary et al. Tumor immunotherapy using adenovirus vaccines in combination with intratumoral doses of CpG ODN
Miller et al. Soluble CD70: a novel immunotherapeutic agent for experimental glioblastoma
Baumgartner et al. Regulation of CD4 T‐cell receptor diversity by vaccine adjuvants
Saha et al. Stimulatory effects of CpG oligodeoxynucleotide on dendritic cell‐based immunotherapy of colon cancer in CEA/HLA‐A2 transgenic mice
Tigno-Aranjuez et al. Dissociated induction of cytotoxicity and DTH by CFA and CpG
Sanchez et al. T9 glioma cells expressing membrane-macrophage colony stimulating factor produce CD4+ T cell-associated protective immunity against T9 intracranial gliomas and systemic immunity against different syngeneic gliomas
HK1164055A (en) Methods and compositions containing mtor inhibitors for enhancing immune responses
Jeon Role of Toll-like Receptor Agonists as Cancer Vaccine Adjuvants
US11850279B2 (en) Platforms and methods for optimizing host antigen presentation and host antitumor and antipathogen immunity
EP2393505B1 (en) Use of specific peptides in the preparation of a medicament for the treatment of monoclonal gammopathy of undetermined significance (mgus) or of smoldering multiple myeloma (smm)
Faries et al. Dendritic cells in melanoma immunotherapy
JP2023525579A (ja) 低免疫原性の細胞および免疫応答におけるそれらの使用
Hess Therapeutic vaccination with ribonucleic acids encoding tumor/self antigens and a cytokine adjuvant in a transgenic murine model of prostatic carcinoma

Legal Events

Date Code Title Description
FZDE Discontinued

Effective date: 20160114